Lipid-lowering therapy: who can benefit? by Lewis, Sandra J
© 2011 Lewis, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 525–534
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
525
ReView
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/VHRM.S23113
Lipid-lowering therapy: who can benefit?
Sandra J Lewis
Northwest Cardiovascular institute, 
Portland, OR, USA
Correspondence: Sandra J Lewis 
Northwest Cardiovascular institute,  
2222 Nw Lovejoy #606,  
Portland, OR 97210, USA 
Tel +1 503 229 7554 
Fax +1 503 248 4612 
email sandral@nw-ci.com
Abstract: Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline 
in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still causes one 
in every six deaths in this country. Because most CHD risk factors are modifiable (eg, smoking, 
hypertension, obesity, onset of type 2 diabetes, and dyslipidemia), cardiovascular risk can be reduced 
by timely and appropriate interventions, such as smoking cessation, diet and lifestyle changes, and 
lipid-modifying therapy. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol 
(LDL-C), is central to the development and progression of atherosclerosis, which can be silent 
for decades before triggering a first major cardiovascular event. Consequently, dyslipidemia has 
become a primary target of intervention in strategies for the prevention of cardiovascular events. 
The guidelines of the Adult Treatment Panel (ATP) III, updated in 2004, recommend therapeutic 
lifestyle changes and the use of lipid-lowering medications, such as statins, to achieve specific LDL-C 
goals based on a person’s global cardiovascular risk. For high-risk individuals, such as patients with 
CHD and diabetic patients without CHD, an LDL-C target of , 100 mg/dL is recommended, and 
statin therapy should be considered to help patients achieve this goal. If correctly dosed in appro-
priate patients, currently approved statins are generally safe and provide significant cardiovascular 
benefits in diverse populations, including women, the elderly, and patients with diabetes. A recent 
primary prevention trial also showed that statins benefit individuals traditionally not considered at 
high risk of CHD, such as those with no hyperlipidemia but elevated C-reactive protein. Additional 
evidence suggests that statins may halt or slow atherosclerotic disease progression. Recent evidence 
confirms the pivotal role of statins in primary and secondary prevention.
Keywords: atherosclerosis, coronary heart disease, dyslipidemia, lipid lowering, primary 
prevention, statin therapy
Introduction
Coronary heart disease (CHD) remains the leading cause of death in both men and 
women in the US.1 In 2006, 18 million of the estimated 81 million adults in the US 
with cardiovascular disease (CVD) had CHD, and more than 400,000 Americans died 
of CHD. CHD is the cause of one in every six deaths in the US.1 However, although 
these statistics are sobering, the age-adjusted death rates for CVD and CHD decreased 
substantially from 1996 to 2006 by 30% and 36%, respectively.1 Population studies 
using validated statistical models have provided compelling evidence that the decrease 
in CHD-related mortality rates is attributable to reductions in modifiable CHD risk 
factors and improvements in evidenced-based medical therapies.2,3
Smoking, hypertension, obesity, type 2 diabetes, and dyslipidemia have long been 
established as important risk factors for CHD.4 The contribution of dyslipidemia Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to   cardiovascular risk was illustrated in a multicenter, 
case-control study conducted in 52 countries showing that 
abnormal lipid levels accounted for approximately 50% of 
the attributable risk for myocardial infarction (MI) in the 
population.5 Consequently, reductions in total cholesterol 
by dietary and other lifestyle changes have been associated 
with more than 20% of the recently observed decrease in 
CHD mortality rates.2,3 Another important factor contribut-
ing to this positive trend has been the availability of powerful 
lipid-lowering therapies, particularly statins. The lipid-
lowering potency of statins and their clinical benefit in terms 
of CHD risk reduction have been established in numerous 
  randomized controlled trials.6 Between 1% and 5% of the 
recent decrease in CHD mortality rates has been attributed 
to the use of statins in primary prevention (ie, individuals 
without established CHD)2,3 and another 9% to the use of sta-
tins by patients with chronic stable coronary artery   disease.3 
Together, these findings confirm that controlling lipid levels 
through lifestyle changes and/or medical treatment is a key 
strategy for primary and secondary prevention of major 
cardiovascular events.
Cardiovascular events, such as MI, often represent the 
end result of years of atherosclerotic disease progression. 
  Atherosclerosis typically starts in early adulthood or even 
youth (in high-risk individuals) and may progress silently 
for decades before CHD symptoms manifest.7 The impor-
tance of dyslipidemia as a likely CHD risk factor is related 
to the central role of specific lipoprotein particles, espe-
cially low-density lipoprotein (LDL), in the   development 
and   progression of atherosclerosis.8 Atherosclerosis is 
  initiated by complex interactions between oxidatively modi-
fied   lipoproteins and components of the immune   system in 
the arterial wall that lead to the formation of fatty streaks and 
fibrous plaques. Plaque build-up and rupture may   ultimately 
lead to progressive stenosis and thrombosis.8 The continuum 
of   atherosclerotic disease progression provides a strong 
rationale for early intervention with lipid-lowering therapy 
in patients with dyslipidemia to prevent the   development 
of CHD later in life. This review discusses the role of 
  lipid-lowering therapy in primary and secondary prevention, 
with particular focus on recent outcome studies of statins. An 
important question that will be examined is: who can benefit 
from lipid-lowering therapy?
Lipid goals
Lipid management is the focus of the current guidelines 
(last updated in 2004) for the reduction of cardiovascular 
risk issued by the National Cholesterol Education Program 
Adult Treatment Panel (ATP) III (available at http://www.
nhlbi.nih.gov/guidelines/cholesterol/).9,10  The ATP III guide-
lines recommend specific lipid goals based on a person’s 
global risk for CHD: the higher the risk, the lower the goal 
(Table 1). For example, an LDL cholesterol (LDL-C) goal 
of , 100 mg/dL was recommended for high-risk persons – ie, 
those with CHD or CHD risk equivalents – while an LDL-C 
goal of , 130 mg/dL was recommended for moderate-risk 
persons who had $ 2 risk factors but no CHD or CHD risk 
equivalents.9,10
Table 1 NCeP ATP iii–recommended LDL-C targets based on a person’s global risk for CHD10
Risk category LDL-C goal Non–HDL-C  
goala
Initiate therapeutic 
lifestyle changes
Consider drug therapy
Very high risk: 
CHD + other risk 
factors or ACS
,70 mg/dL (optional) ,100 mg/dL $100 mg/dL $100 mg/dL 
(,100 mg/dL: consider 
drug options)
High risk: CHD or 
risk equivalents 
(10-year risk . 20%)
,100 mg/dL ,130 mg/dL $100 mg/dL $100 mg/dL 
(,100 mg/dL: consider 
drug options)
Moderately high 
risk: $ 2 risk 
factors (10-year risk 
10%–20%)
,130 mg/dL 
(optional: ,100 mg/dL)
,160 mg/dL $130 mg/dL $130 mg/dL 
(100 to 129 mg/dL: 
consider drug options)
Moderate risk: $ 2 
risk factors (10-year 
risk , 10%)
,130 mg/dL ,160 mg/dL $130 mg/dL $160 mg/dL
Lower risk: 0 to 1 
risk factor
,160 mg/dL ,190 mg/dL $160 mg/dL $190 mg/dL 
(160 to 189 mg/dL: 
consider drug options)
Note: ain patients with elevated triglycerides ($ 200 mg/dL).
Abbreviations: ACS, acute coronary syndrome; CHD, coronary heart disease; non–HDL-C, non–high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; NCeP ATP iii, National Cholesterol education Program Adult Treatment Panel iii guidelines.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Lipid management in the US has improved since the 
2004 update of the ATP III guidelines. Based on a 2003 
survey, 67% of adults at risk of CHD achieved the ATP 
III–recommended LDL-C goals.11 This number increased to 
76% in a more recent survey conducted in 2006 and 2007.12 
However, substantial room for improvement in lipid goal 
attainment remains, especially for persons at high risk or very 
high risk of CHD. In both surveys, treatment success rates 
were considerably lower for these persons than for persons 
at low risk.11,12
Therapeutic lifestyle changes  
for all at-risk persons
Therapeutic lifestyle changes – increased physical   activity, 
weight loss, smoking cessation, and adoption of a healthier 
diet – effectively reduce cardiovascular risk in primary13–15 
and secondary prevention.16,17 Lifestyle changes should 
be the primary focus and first step of a cardiovascular 
risk reduction strategy for any person at risk for CHD.10 
However, it is important to acknowledge that lifestyle 
intervention is not always an achievable or successful 
approach for attaining recommended lipid goals. Some 
individuals may be unable or unwilling or may lack the 
opportunity to fully comply with dietary and other lifestyle 
recommendations. Others may not be able to reach their 
lipid goals despite their best efforts at lifestyle changes.
Who can benefit from  
lipid-lowering therapy?
evidence before updated ATP iii
The 2001 ATP III guidelines recommend the use of 
  lipid-lowering pharmacotherapy for individuals who are 
unable to meet their recommended LDL-C goals with thera-
peutic lifestyle changes and for higher-risk   individuals.9 
Taking into account new evidence from five outcome 
  trials of statin therapy, the guidelines were updated in 
2004 (Table 1).
The Heart Protection Study was a placebo-controlled 
primary prevention study of simvastatin conducted in the UK 
in more than 20,000 adults at high risk of a cardiovascular 
event. The study results revealed a 13% lower all-cause 
mortality rate (P = 0.0003) and a 24% lower rate in major 
vascular events (P , 0.0001) for simvastatin vs placebo.18 
Subgroup analyses of the study further suggested that the 
vascular benefits of simvastatin extended to a wide variety 
of high-risk individuals, including women, older individuals, 
individuals with no CHD but with other vascular diseases 
or diabetes, and individuals with LDL-C , 116 mg/dL or 
total cholesterol , 193 mg/dL.18,19 In study participants with 
diabetes, simvastatin vs placebo reduced the   occurrence of a 
first major vascular event by 22% (P , 0.0001).19   Diabetic 
individuals who benefited from simvastatin therapy included 
those without occlusive arterial disease and those with 
LDL-C , 116 mg/dL at baseline.19 Thus, the findings from 
the Heart Protection Study strongly suggested that lipid-
lowering therapy with statins can provide primary   prevention 
benefits for high-risk individuals, even in the absence of 
hyperlipidemia.
The efficacy of statin therapy in elderly patients with 
or at high risk of stroke or CVD was demonstrated in the 
  Prospective Study of Pravastatin in the Elderly at Risk 
(PROSPER). In this study, pravastatin was associated 
with a modest but significant reduction in the risk for the 
  composite end point of CHD mortality, stroke, and   nonfatal 
MI,   compared with placebo (hazard ratio [HR]: 0.85; 
P = 0.014).20
The results of the Pravastatin or Atorvastatin   Evaluation 
and Infection Therapy–Thrombolysis in Myocardial 
  Infarction 22 (PROVE IT–TIMI 22) study provided   evidence 
that in patients who have acute coronary syndrome (ACS), 
an intensive lipid-lowering statin regimen may be war-
ranted. In this comparative study, intensive therapy with 
atorvastatin 80 mg was significantly more effective than 
standard therapy with pravastatin 40 mg in reducing LDL-C 
levels well below the 100-mg/dL goal for high-risk patients 
(62 mg/dL with intensive therapy vs 95 mg/dL with standard 
therapy).   Importantly, the more effective LDL-C reduction 
with intensive therapy was accompanied by a significantly 
greater reduction in the risk of the composite primary end 
point of death from any cause, MI, unstable angina requiring 
rehospitalization, revascularization, and stroke (relative risk 
[RR] reduction: 16%; P = 0.005).21
Two primary prevention studies evaluated the clinical 
benefits of statin therapy in hypertensive and moderately 
hypercholesterolemic patients at moderately high risk 
for CHD. In the Anglo-Scandinavian Cardiac Outcomes 
Trial–Lipid-Lowering Arm (ASCOT–LLA), the addition of 
atorvastatin to antihypertensive therapy decreased LDL-C 
to 87 mg/dL (placebo, 133 mg/dL) – a level substantially 
below the goal of 130 mg/dL for moderate-risk patients – and 
significantly reduced the incidence of nonfatal MI and fatal 
CHD (HR: 0.64; P = 0.0005).22 In contrast, the Antihyperten-
sive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT–LLT) found no significant reduction in the 
risk of all-cause mortality (primary end point) or in the risk Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of CHD events with pravastatin vs usual care in this patient 
population. A possible explanation for this negative result 
is the modest difference observed between the mean LDL-C 
values achieved with pravastatin (111 mg/dL) and usual care 
(135 mg/dL) after 2 years of treatment.23
The results of these five statin trials led to the 2004 update 
of the ATP III guidelines (originally published in 2001).10 For 
high-risk and moderate-risk persons, the updated guidelines 
recommend LDL-C goals of , 100 mg/dL and , 130 mg/dL, 
respectively (Table 1). Regardless of the recommended goal, 
lipid-modifying therapy in a high-risk or moderate-risk 
person should have sufficient intensity to achieve at least a 
30% to 40% reduction in LDL-C. For persons at very high 
risk, such as those with established CHD plus additional risk 
factors (eg, type 2 diabetes), LDL-C , 70 mg/dL is recom-
mended as an optional therapeutic goal.10
evidence since updated ATP iii guidelines
The significant clinical benefits of statin therapy across 
populations with a wide variety of patient characteristics are 
well established. The results of a prospective meta-analysis 
of data from 90,056 participants in 14 randomized statin tri-
als suggested that the absolute benefits of treatment in terms 
of risk reduction largely depend on the risk at baseline and 
the absolute reduction in LDL-C achieved.24 The benefits 
of statin therapy were confirmed recently by the results of 
a large network meta-analysis of 76 randomized controlled 
trials with a total of more than 170,000 participants.25 
  Statin therapy vs placebo or usual care was associated with 
significant reductions in the risk of death from any cause 
(RR: 0.90; P # 0.0001), death from cardiovascular causes 
(RR: 0.80; P , 0.0001), nonfatal MI (RR: 0.74; P # 0.001), 
and revascularization procedures (RR: 0.76; P # 0.0001).25 
Importantly, a highly significant reduction in the incidence of 
death from CVD with statin therapy vs control was observed 
both in individuals with established CHD (RR: 0.82; 95% 
confidence interval [CI]: 0.76–0.88) and in primary preven-
tion (RR: 0.81; 95% CI: 0.75–0.87).25
Secondary prevention
The meta-analysis by Mills et al25 included 42 studies of patients 
with CHD as the primary study population. In these patients, 
statin therapy vs control was associated with a RR reduction 
of 18% for cardiovascular death.25 A number of previous 
meta-analyses also demonstrated the clinical benefits of statin 
therapy in secondary prevention (Table 2). A meta-analysis of 
nine placebo-controlled trials of statins that included previously 
unpublished data demonstrated a 22% reduction in all-cause 
mortality among elderly patients (aged 65–82 years) with 
CHD (Table 2).26 In addition, two meta-analyses of data from 
patients with ACS suggested that more intensive lipid-lowering 
therapy is associated with greater benefits in this population. 
In the first meta-analysis, data from 13 randomized controlled 
trials in patients with ACS showed that intensive statin therapy, 
compared with standard statin therapy, reduced the incidence of 
adverse cardiovascular outcomes when started within 14 days 
of hospitalization for ACS27 (Table 2). Similarly, in the second 
meta-analysis, data from patients with ACS or stable CHD who 
participated in the Treating to New Targets (TNT), Incremental 
Decrease in End Points Through Aggressive Lipid-Lowering 
(IDEAL), PROVE IT–TIMI 22, or Aggrastat-to-Zocor (A-to-Z) 
studies showed significantly greater efficacy of high-dose vs 
standard-dose statin therapy in reducing the risk of cardiovas-
cular events, including coronary death (Table 2).28
Despite the overwhelming evidence for significant clinical 
benefits of statin therapy in patients with CHD, trials designed to 
demonstrate similar benefits in patients with heart failure have 
been unsuccessful. The Controlled Rosuvastatin   Multinational 
Study in Heart Failure (CORONA) evaluated the effects of 
rosuvastatin 10 mg/day on the composite primary end point of 
cardiovascular death, nonfatal MI, or nonfatal stroke in more 
than 5000 patients aged $ 60 years with systolic heart failure.29 
Although rosuvastatin significantly reduced the incidence of 
hospitalization for cardiovascular causes, compared with pla-
cebo, it provided no significant benefit related to the primary 
end point (Table 2).29 Similarly, in a recent placebo-controlled 
study conducted in Italy, rosuvastatin 10 mg had no significant 
effects on the primary end point of death or hospitalization for 
cardiovascular reasons in patients with chronic heart failure 
(Table 2).30 Lipid-lowering therapy with statins also has not 
been shown to provide significant benefits in patients with end-
stage kidney disease requiring maintenance hemodialysis.31,32 
However, in the Study of Heart and Renal Protection (SHARP), 
which included more than 9000 patients with chronic kidney 
disease but no history of MI or coronary revascularization, the 
combination of simvastatin 20 mg and ezetimibe 10 mg pro-
vided a significant 17% reduction (95% CI: 6–26; P = 0.002) 
in atherosclerotic events (including first nonfatal MI, coronary 
death, nonhemorrhagic stroke, and coronary or noncoronary 
revascularization), compared with placebo.33
Primary prevention
The updated ATP III guidelines emphasize that lipid-lowering 
therapy can provide benefits for high-risk individuals, includ-
ing those with diabetes, even if they have no obvious signs of 
  hyperlipidemia. The results of the Collaborative Atorvastatin Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Diabetes Study (CARDS) confirmed the primary prevention 
benefit of statin therapy in diabetic patients without high 
  LDL-C.34 CARDS showed that atorvastatin 10 mg daily reduced 
the rate of first major cardiovascular events, including ACS, 
coronary revascularization, and stroke, by 37% (P = 0.001) 
compared with placebo (Table 3).34 Patients with diabetes 
generally have higher triglycerides and lower high-density 
lipoprotein cholesterol (HDL-C) levels, which are associated 
with an increased risk for cardiovascular events.35 In the FIELD 
trial, fenofibrate, a drug that lowers triglycerides and increases 
HDL-C, was shown to provide some benefits for patients with 
type 2 diabetes, such as reducing the rate of nonfatal MI and cor-
onary revascularization, but beneficial effects on CHD-related 
mortality could not be demonstrated.36 Results of the Action 
to Control Cardiovascular Risk in   Diabetes (ACCORD) Lipid 
Study further suggest that addition of fenofibrate to simvastatin 
provides no cardiovascular benefits for patients with diabetes 
beyond those conferred by simvastatin alone.37 However, 
combination therapy with fenofibrate and   simvastatin may be 
appropriate for patients with diabetes with mixed dyslipidemia 
(triglycerides $ 204 mg/dL and HDL-C # 34 mg/dL), based 
on the results of a prespecified subgroup analysis of ACCORD 
showing that addition of fenofibrate to simvastatin lowered the 
incidence of CVD events by 31% in these patients.37
Findings from the recent Justification for the Use of 
Statins in Prevention: an Intervention Trial Evaluating 
Rosuvastatin (JUPITER) (Table 3) demonstrated that statin 
therapy may provide cardiovascular benefits for healthy 
individuals who do not meet the current ATP III criteria 
for high CVD risk.38 JUPITER was a large, double-blind, 
placebo-controlled study that evaluated the efficacy of 
rosuvastatin in the primary prevention of cardiovascular 
death and vascular events in 17,802 men (aged $ 50 years) 
and women (aged $ 60 years) from 26 countries who had 
LDL-C , 130 mg/dL but plasma concentrations of high-
sensitivity C-reactive protein $ 2 mg/L.38 Compared with 
placebo, rosuvastatin 20 mg/day significantly reduced the 
incidence of major cardiovascular events by 44%, including 
MI (HR: 0.46; 95% CI: 0.30–0.70), stroke (HR: 0.52; 95% 
CI: 0.34–0.79), and arterial revascularization (HR: 0.54; 
95% CI: 0.41–0.72).38 Because the differences in clinical 
efficacy between rosuvastatin and placebo were of high 
clinical and statistical significance, JUPITER was halted 
by an independent data and safety monitoring board after a 
median follow-up period of 1.9 years.38
Despite the results of JUPITER, which showed a sig-
nificant reduction in all-cause mortality with rosuvastatin vs 
placebo in patients without CHD, the effect of statin therapy on 
  all-cause mortality in primary prevention remains a subject of 
  controversy. Although many meta-analyses of primary preven-
tion trials clearly demonstrated that statin therapy may provide 
important cardiovascular benefits in individuals without CHD, 
findings for all-cause mortality have been mixed in terms of the 
statistical significance of statin-related benefit (Table 4).6,39–42 
A recent meta-analysis of eleven primary prevention trials that 
included 65,229 adults without clinically manifest CHD found a 
9% reduction in the risk of all-cause mortality for statin therapy 
vs placebo that missed statistical significance (Table 4).39 
In contrast, another recently published meta-analysis of ten pri-
mary prevention studies comprising 70,388 individuals found 
that statin therapy vs placebo significantly reduced the risk of 
all-cause mortality by 12% (Table 4).42 In the latter analysis, 
6% of participants had had a previous cardiovascular event. 
Exclusion from the analysis of the three studies that recruited 
these individuals did not affect the outcome substantially 
because statin therapy was still associated with a significant 
reduction of 13% in the RR of all-cause mortality. In addition, 
even after the exclusion of JUPITER from the meta-analysis, 
RR reduction in all-cause mortality with statin therapy (11% 
vs placebo) remained statistically significant.42 Consistent with 
these findings, a recently published Cochrane database analysis 
of 14 primary prevention studies (not including JUPITER) 
across diverse study populations found statistically significant 
reductions with statins in risks of all-cause mortality (RR: 0.83; 
95% CI: 0.73–0.95), combined fatal and nonfatal CVD events 
(RR: 0.70; 95% CI: 0.61–0.79), and revascularization (RR: 
0.66; 95% CI: 0.53–0.83).40 The differences in the results of 
these meta-analyses regarding the effects of statins on all-cause 
mortality may be due at least in part to the differences in the 
selection of trials and data, potentially resulting in differences 
in the representation of risk categories among analysis popula-
tions (Table 4). Moreover, in study populations with substantial 
proportions of low-risk individuals, much longer follow-up 
times may be required to demonstrate a significant treatment 
effect on all-cause mortality than to demonstrate significant 
benefits related to composite end points.
Effect of lipid-lowering therapy on  
atherosclerotic disease progression
Several clinical studies evaluated the effect of statins on 
atherosclerotic disease progression in individuals with 
or without CHD. For patients with established CHD, the 
Reversal of Atherosclerosis with Aggressive Lipid   Lowering 
(REVERSAL) trial showed that intensive therapy with high-
dose atorvastatin reduced the progression of coronary athero-
sclerosis compared with standard-dose pravastatin.43 A Study Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to Evaluate the Effect of Rosuvastatin on Intravascular 
Ultrasound-Derived Coronary Atheroma Burden (ASTER-
OID) further demonstrated that intensive lipid lowering with 
high-dose rosuvastatin, achieving average LDL-C levels of 
61 mg/dL (53% reduction) and HDL-C increases of 6 mg/dL 
(15%), resulted in significant regression of coronary ath-
erosclerosis.44 Similarly, the Stop Atherosclerosis in Native 
Diabetics Study (SANDS) showed that intensive therapy 
lowering LDL-C to # 70 mg/dL resulted in the regression 
of carotid intima-media thickness (CIMT) in patients with 
type 2 diabetes and no prior cardiovascular event.45 Statins 
have also been shown to provide benefits for asymptomatic 
patients with subclinical atherosclerosis. In the Measuring 
Effects on Intima-Media Thickness: an Evaluation of Rosu-
vastatin (METEOR) study, 2 years of intensive therapy with 
rosuvastatin, compared with placebo, significantly slowed 
the progression of carotid atherosclerotic lesions in patients 
with low Framingham risk scores, slightly elevated LDL-C, 
and modestly increased CIMT.46
Overall, the findings from these studies are consis-
tent with the clinical benefits of intensive lipid-lowering 
therapy observed in trials with clinical end points and 
suggest that the aggressive LDL-C goal of , 70 mg/dL 
may be beneficial for specific patient groups, such as high-
risk patients with established CHD or type 2 diabetes. In 
addition, some findings suggest that statins may slow the 
progression of atherosclerosis in asymptomatic low-risk 
patients, for whom the ATP III guidelines currently do 
not recommend the use of statins. These findings need to 
be confirmed in randomized controlled trials evaluating 
vascular outcomes.
Safety
Statin therapy is generally safe and well tolerated, and adverse 
events associated with statins are well documented.24,25 Among 
adverse effects of statin therapy, abnormalities in liver metab-
olism and myopathy are of particular concern.   Symptoms 
of myopathy, such as myalgia, vary widely among persons 
taking statins in routine clinical practice (0.3% to 33%), but 
rhabdomyolysis, a serious and potentially fatal myopathy, 
is rare.47 A meta-analysis of 76 randomized controlled statin 
trials found that statin therapy significantly increased levels of 
aspartate aminotransferase (odds ratio [OR]: 1.12; P = 0.005) 
and alanine aminotransferase (OR: 1.3; P # 0.001), but not 
creatine kinase (OR: 1.07; P = 0.66).25 Most importantly, statin 
therapy, compared with control treatment, was not associated 
with a significantly increased risk of rhabdomyolysis (OR: 
1.04; P = 0.73). Overall, rates of rhabdomyolysis were low 
and virtually identical (0.25%) in statin and control groups 
across 35 studies that included data from more than 130,000 
participants.25 However, although the absolute risk of statin-
related rhabdomyolysis is generally low, it may be increased 
in specific patients by a number of patient and treatment 
characteristics, including high statin doses, statin cytochrome 
metabolism, advanced age, specific comorbidities (eg, liver 
dysfunction), drug interaction of statins with concomitant 
medications, and genetic risk factors.47
A recently emerged concern is the increase in incident 
diabetes observed with statin therapy in some clinical 
studies.22,29,38 A meta-analysis of 13 major cardiovascular 
trials that evaluated the incidence of diabetes in more than 
90,000 nondiabetic participants found that statin therapy 
was associated with a small risk of developing diabetes 
Table 4 Clinical effects of statins on all-cause mortality in primary prevention: findings from recent meta-analyses
Meta-analysis Follow-upa Population LDL-C All-cause Mortality
Baseline Reduction No. of deaths/no.  
of patients
Risk reduction  
(95% CI)
Thavendiranathan  
et al41
3.2-5.2 years N = 42,848 (7 trials)b 
90% without CVD
147 mg/dL 
(mean)
-26.1% N/A 0.92 (0.84-1.01)  
P = 0.09
Mills et al6 1.0-5.3 yearsc N = 63,899 (19 trials)b 
59.6%–100% without 
CHD
N/A N/A N/A 0.93 (0.87-0.99)  
P = 0.03
Brugts et al42 4.1 years N = 70,388 (10 trials) 
94% without CVD
140 mg/dLd 
(mean)
-25.6% 1725/33,683e
1925/33,793f
0.88 (0.81-0.96)
Ray et al39 3.7 years N = 65,229 (11 trials) 
100% without CVD
138 mg/dL -40 mg/dLg  1346/32,623e
1447/32,606f
0.91 (0.83-1.01)
Taylor et al40 1.0-5.3 years N = 34,272 (14 trials)b 
$ 90% without CVD
153 mg/dLd 
(median)
-36 mg/dLd,g 794/28,161 (2.8%) 0.83 (0.73-0.95)
Notes: aBased on mean and median follow-ups of the individual studies; bdid not include JUPiTeR; cvalues shown are follow-up durations or patient characteristics of individual 
trials included in the meta-analysis; dconverted from Si units (mmol/L) using 38.61 as conversion factor; estatin group; fcontrol group; gvs control.
Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; JUPITER, Justification for the Use of Statins in Prevention: an Intervention 
Trial evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; N/A, not available.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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(OR: 1.09; 95% CI: 1.02–1.17) over a period of 4 years.48 
The increased risk of diabetes primarily affected elderly 
individuals and appeared not to be associated with the 
extent of LDL-C reduction.48 These findings suggest that 
it is important to closely monitor older patients on statin 
therapy for signs of dysglycemia. However, it is also impor-
tant to emphasize that the large cardiovascular benefits of 
statin therapy in primary and secondary prevention clearly 
outweigh the relatively small risk of incident diabetes associ-
ated with statin use.48
Conclusion
Clinical data published during the past decade have provided 
compelling evidence that lipid-lowering therapy with sta-
tins is a powerful therapeutic approach in the primary and 
secondary prevention of negative cardiovascular outcomes. 
Statin therapy may benefit high-risk individuals with diverse 
demographic and clinical characteristics, including women, 
the elderly, patients with type 2 diabetes, and high-risk indi-
viduals without hyperlipidemia. Moreover, recent results 
suggest that the treatment benefits of statins may extend 
to individuals traditionally not considered at high risk for 
CHD, such as those with elevated C-reactive protein but 
normal lipid levels. The demonstrated efficacy of statins 
in primary prevention together with their potential to slow 
atherosclerotic disease progression provides a strong argu-
ment in favor of starting lipid-lowering therapy as early 
as possible. In patients with established CHD, intensive 
lipid-lowering therapy is more effective than less-intensive 
therapy in reducing lipid levels to recommended goals and 
in reducing the risk of cardiovascular events, CHD mor-
tality, and all-cause mortality. The failure to demonstrate 
significant benefits of statin therapy in patients with heart 
failure and in those requiring hemodialysis suggests that 
in many patients with very advanced stages of disease, 
intervention with statins may be too late to affect outcomes 
or impact end-of-life events not related to cardiovascular 
risk reduction.
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